3 results
Approved WMORecruiting
The primary objective of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progressionfree survival (PFS) (by independent imaging…
Approved WMORecruiting
The objective of the study is to evaluate the safety and performance of a new Non-Invasive Ultrasound Therapy (NIUT) with Valvosoft® in the treatment of CAS.
Approved WMOCompleted
To demonstrate the safety and effectiveness of the IntellaNav StablePoint Catheter and Force Sensing System with DIRECTSENSE for treatment of drug refractory, recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF).